Astec LifeSciences Limited has initiated a postal ballot process to seek shareholder approval for related party transactions with its holding companies, Godrej Agrovet Limited and Godrej Industries Limited, for the financial year 2026-27. The company proposes to enter into transactions worth an aggregate of ₹405 crore, subject to arm’s length pricing and ordinary course of business conditions. The resolutions also include the appointment of Mr. Arijit Mukherjee as Executive Director and the elevation of Mr. Vishal Sharma and Mr. Burjis N. Godrej to the Board.

The Board of Directors, based on the recommendation of the Audit Committee, has identified that the proposed transactions exceed the materiality threshold defined under Regulation 23(4) of the SEBI Listing Regulations. Consequently, shareholder approval is required to ratify these arrangements. The company stated that these transactions are expected to enhance capacity utilisation and improve operational efficiency by leveraging group synergies.

Related Party Transactions

The company has proposed an aggregate limit of ₹300 crore for transactions with Godrej Agrovet Limited, its holding company, and ₹105 crore for transactions with Godrej Industries Limited, its ultimate holding company. These limits cover the sale and purchase of goods, services, and inter-corporate deposits. The transactions will be valid for the financial year 2026-27.

The company’s consolidated turnover for the financial year 2025-26 was ₹45,321.65 lakh. The proposed limits represent 66.19% and 23.17% of the annual consolidated turnover for transactions with Godrej Agrovet Limited and Godrej Industries Limited, respectively.

Director Appointments

Shareholders are also asked to approve the appointment of Mr. Arijit Mukherjee as an Executive Director for a term of three years from April 13, 2026, to April 12, 2029. His remuneration package includes a basic salary range of ₹35 lakh to ₹42 lakh per annum, allowances and perquisites ranging from ₹1.18 crore to ₹1.40 crore, and a performance-linked variable remuneration of up to ₹36 lakh. Additionally, the appointment of Mr. Vishal Sharma and Mr. Burjis N. Godrej as Non-Executive, Non-Independent Directors, and Mr. Mathew Eipe as an Independent Director, are up for approval.

Voting Process

The e-voting facility will be available from 9.00 a.m. (IST) on June 5, 2026, until 5.00 p.m. (IST) on July 4, 2026. Members holding shares as of the cut-off date, May 29, 2026, are eligible to vote. The results of the postal ballot will be declared within two working days from the close of voting. Mr. Vikas R. Chomal, Practicing Company Secretary, has been appointed as the Scrutinizer for the process.

Astec LifeSciences Limited has announced the grant of 1,142 stock options to an eligible employee under its Employee Stock Option Plan 2012 (ESOP 2012). The grant was approved by the company's Nomination and Remuneration Committee on April 30, 2026, in compliance with regulatory requirements.

Stock Option Grant Details

The company has provided comprehensive details regarding the stock option grant structure and terms:

Each stock option entitles the holder to apply for one equity share of the company with a face value of Rs.10/-. The exercise price has been set at Rs.10/- per option, matching the face value of the underlying shares.

Regulatory Compliance and Framework

The stock option grant has been structured in accordance with multiple regulatory frameworks to ensure full compliance. The grant falls under the provisions of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. Additionally, the announcement has been made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Vesting and Exercise Terms

The granted options follow a structured vesting schedule designed to align employee interests with long-term company performance. The options will vest over a period of 3 years, providing a gradual release of benefits to the eligible employee. Once vested, the options must be exercised within 1 month from the date of vesting, though the Nomination and Remuneration Committee retains the authority to determine alternative exercise periods if deemed appropriate.

Corporate Communication and Documentation

Astec LifeSciences has ensured transparent communication of this development through multiple channels. The company has formally notified both BSE Limited and National Stock Exchange of India Limited about the stock option grant through official regulatory filing. The communication was signed by Tejashree Pradhan, Company Secretary & Compliance Officer, and the information has also been uploaded on the company's official website at www.godrejastec.com , ensuring accessibility for all stakeholders and maintaining compliance with disclosure requirements.